Key result
Hancock porcine bioprosthetic valves demonstrate ~6% operative mortality and low thromboembolism rates.
Why the study?
Long-term clinical experience and durability data for the Hancock porcine bioprosthetic heart valve were needed to assess survival, thromboemboli, and valve function.
What are the long-term survival, thromboembolic risk, and durability of the Hancock porcine bioprosthetic heart valve?
Cohort (n=467)
What are the long-term survival, thromboembolic risk, and durability of the Hancock porcine bioprosthetic heart valve?
The Hancock porcine bioprosthetic heart valve demonstrates acceptable durability over 6 years with a low incidence of thromboemboli in patients without chronic atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Supports durability data for Hancock valve in non-AF patients; extends observational reports but leaves open randomized comparisons.
Clinical experience with the Hancock porcine bioprosthetic heart valve was reviewed in 467 patients (254 men and 213 women, 18--84 years old, average, 56 years) who received 528 valves from January, 1972, to January, 1978. Associated procedures, including coronary bypass graft, ascending aortic aneurysm, and valvuloplasty were done in 102 of the 467 patients (22%). The overall operative mortality was 25/467 (5.6%), 12/226 (5.3%) for aortic valve replacement (AVR), 11/183 (6%) for mitral valve replacement (MVR), and 2/58 (3.4%) for multiple valve replacement. The first 323 patients with a minimum follow-up of 16 months (16--75 months, average 33 months) were analyzed for survival and thromboemboli. Actuarial survival at 66--75 months was 75.7% for AVR, 79% for MVR, and 75.8% for multiple valve replacement. Emboli per 100 patient-years was 0.55 for AVR (no anticoagulants), 3.9 for MVR, and 4.8 for multiple valve replacement (anticoagulants for atrial fibrillation patients only); emboli occurred only in patients with atrial fibrillation. There were seven of 528 primary dysfunctional valves (1.3%): calcification in two, tissue failure in two, and fibrosis in three. A hemodynamic study of four patients with a 21 mm Hancock Modified Orifice aortic valve prosthesis showed improved orifice areas (greater than 1.3 cm2) over the standard aortic valve. The Hancock porcine xenograft bioprosthetic heart valve has been a durable heart valve in excess of 6 years and has a low associated incidence of thromboemboli in patients off anticoagulants except in those with chronic atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Cohen et al. (1979) conducted a cohort in Valvular heart disease requiring valve replacement (n=467). Hancock porcine bioprosthetic heart valve was evaluated on Overall operative mortality. The Hancock porcine bioprosthetic heart valve demonstrated an overall operative mortality of 5.6% and actuarial survival of 75.7% to 79% at 66-75 months, with a low incidence of thromboemboli.
Synapse has enriched 10 related papers. Consider them for comparative context: